Repligen Corporation (RGEN)

Currency in USD
145.34
+14.28(+10.90%)
Closed·
147.00+1.66(+1.14%)
·
Earnings results expected today
RGEN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
137.35154.00
52 wk Range
100.99175.77
Key Statistics
Prev. Close
131.06
Open
139.7
Day's Range
137.35-154
52 wk Range
100.99-175.77
Volume
2.44M
Average Volume (3m)
1.23M
1-Year Change
21.471%
Book Value / Share
37.38
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RGEN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
178.05
Upside
+22.51%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth

Repligen Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

19 Buy
3 Hold
0 Sell
Ratings:
22 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 178.05
(+22.51% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Jefferies
Hold160.00+10.09%142.00MaintainJul 28, 2026
Canaccord
Hold145.00-0.23%-MaintainJul 23, 2026
Benchmark
Buy185.00+27.29%-UpgradeJul 07, 2026
HSBC
Buy150.00+3.21%170.00MaintainJun 03, 2026
Wolfe Research
Buy145.00-0.23%-New CoverageJun 01, 2026

Repligen Corporation SWOT Analysis


Bioprocessing Pionee
Repligen leads the $12B bioprocessing market with innovative technologies, strategic acquisitions, and a focus on new modalities driving growth
Financial Resilience
Despite market challenges, Repligen maintains strong financials with a 51.15% gross profit margin and upward revenue guidance for 2025
Market Dominance
Explore Repligen's unique position, with 80% of its portfolio facing little to no competition, fostering pricing power and market leadership
Future Trajectory
Analyst targets range from $150 to $220, reflecting varied views on Repligen's growth potential amid industry recovery and expansion
Read full SWOT analysis

Repligen Corporation Earnings Call Summary for Q2/2026

  • Repligen Q2 adjusted EPS of $0.54 beat estimates by 20%; revenue rose 12% YoY to $204M, topping forecasts by $2.53M amid strong demand.
  • Company raised FY2026 guidance: revenue $813M-$834M (10.5%-13.5% organic growth), adjusted EPS $2.03-$2.09, operating margin 15.7%-16.0%.
  • Proteins segment surged 50%, analytics grew 30%+; filtration remained weak with mid-single-digit growth expected due to Polymem sale and headwinds.
  • Shares jumped 6.21% premarket to $139.20; company delivered 12th consecutive quarter meeting or beating expectations, signaling sustained execution.
  • BioLife acquisition expected to close Q4, expanding cell therapy strategy; management noted Q3 margins will be lowest of year due to product mix.
Last Updated: 2026-07-28, 09:16 a/m
Read Full Transcript

Earnings

Latest Release
Jul 28, 2026
EPS / Forecast
0.54 / 0.45
Revenue / Forecast
204M / 201.47M
EPS Revisions
Last 90 days

RGEN Income Statement

Compare RGEN to Peers and Sector

Metrics to compare
RGEN
Peers
Sector
Relationship
P/E Ratio
143.9x12.7x−0.4x
PEG Ratio
0.450.020.00
Price/Book
3.5x4.8x2.6x
Price / LTM Sales
9.7x3.0x2.9x
Upside (Analyst Target)
37.3%7.8%56.8%
Fair Value Upside
Unlock−0.2%8.9%Unlock

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company’s products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
34.73M61.57%4.55B
Other Institutional Investors
35.48M38.43%4.65B
Public Companies & Retail Investors
0.000.00%0.00
Total
70.21M100.00%9.2B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
T. Rowe Price Group, Inc.11.07%6,244,821818,446
BlackRock, Inc.10.62%5,993,054785,450

People Also Watch

72.10
TECH
+0.67%
66.77
PNR
+5.67%
46.12
MTDR
-2.23%
85.77
ARWR
+0.28%
80.58
GMED
+2.98%

FAQ

What Is the Repligen (RGEN) Stock Price Today?

The Repligen stock price today is 145.34 USD.

What Stock Exchange Does Repligen Trade On?

Repligen is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Repligen?

The stock symbol for Repligen is "RGEN."

What Is the Repligen Market Cap?

As of today, Repligen market cap is 8.24B USD.

What Is Repligen's Earnings Per Share (TTM)?

The Repligen EPS (TTM) is 0.91.

When Is the Next Repligen Earnings Date?

Repligen will release its next earnings report on Jul 28, 2026.

From a Technical Analysis Perspective, Is RGEN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Repligen Stock Split?

Repligen has split 0 times.

How Many Employees Does Repligen Have?

Repligen has 2000 employees.

What is the current trading status of Repligen (RGEN)?

As of Jul 28, 2026, Repligen (RGEN) is trading at a price of 145.34 USD, with a previous close of 131.06 USD. The stock has fluctuated within a day range of 137.35 USD to 154.00 USD, while its 52-week range spans from 100.99 USD to 175.77 USD.

What Is Repligen (RGEN) Price Target According to Analysts?

The average 12-month price target for Repligen is 178.05 USD, with a high estimate of 220 USD and a low estimate of 142 USD. 19 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +22.51% Upside potential.

What Is the RGEN Premarket Price?

RGEN's last pre-market stock price is 139.20 USD. The pre-market share volume is 350.00, and the stock has decreased by 8.14, or 6.21%.

What Is the RGEN After Hours Price?

RGEN's last after hours stock price is 147.00 USD, the stock has decreased by 1.66, or 1.14%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.